rs4151667 — CFB L9H

CFB L9H — A Signal Peptide Variant That Quiets the Complement Fire

Complement factor B (CFB) is the gatekeeping enzyme of the alternative complement pathway — the arm of innate immunity that amplifies inflammatory destruction against pathogens, dead cells, and, in the wrong circumstances, healthy tissue. When factor B binds to C3b¹¹ C3b
the activated form of complement component 3 that acts as an opsonin and amplification hub and forms the C3 convertase complex, it triggers a cascade that deposits inflammatory mediators, recruits immune cells, and, in the retina, damages the delicate photoreceptor support layer. The rs4151667 L9H variant sits in the signal peptide of CFB — the molecular zip code that directs the newly synthesized protein into the secretory pathway — and is one of only two protective non-synonymous variants in the CFB gene with established AMD association. Carriers of the protective A allele have approximately 50% lower odds of developing age-related macular degeneration (AMD), one of the leading causes of irreversible vision loss in adults over 65.

The Mechanism

The L9H substitution (leucine to histidine at position 9) lies within the CFB signal peptide, the short hydrophobic leader sequence encoded by exon 1 that is cleaved co-translationally as the protein enters the endoplasmic reticulum. Signal peptide variants can alter secretion efficiency, folding kinetics, or the quantity of mature protein released into circulation. The functional consequence of L9H has not been fully characterized at the molecular level²² The functional consequence of L9H has not been fully characterized at the molecular level
Gold et al. 2006 acknowledged that direct functional demonstration was lacking but proposed that L9H could modulate CFB secretion and therefore the supply of factor B available for convertase assembly. A plausible model is that the histidine substitution subtly reduces secretion efficiency, producing slightly less circulating factor B — reducing the steady-state availability of the substrate needed for C3 convertase assembly and thereby dampening basal alternative pathway tick-over.

L9H is in nearly complete linkage disequilibrium (LD) with the C2 E318D variant (rs9332739), forming the well-characterized protective haplotype H10. The co-occurrence of these two variants in cis means that the AMD protection attributed to L9H likely reflects the combined effect of reduced CFB secretion efficiency and altered C2 classical pathway activity, and it remains difficult to disentangle the independent contribution of each polymorphism. The functionally better-characterised CFB R32Q variant (rs641153)³³ CFB R32Q variant (rs641153)
a missense variant at codon 32 in the Ba domain; Q32 binds C3b with up to 4× lower affinity than R32, directly reducing C3 convertase formation is on a distinct protective haplotype (H7) in high LD with C2 rs9332739 but not with L9H, and serves as a mechanistic model for how reduced CFB activity protects the complement-vulnerable retinal pigment epithelium.

The Evidence

The initial discovery of CFB L9H as an AMD protective variant came from a 2006 landmark Nature Genetics study by Gold et al.⁴⁴ Nature Genetics study by Gold et al.
Two independent cohorts totalling ~900 AMD cases and ~400 controls; protective haplotype H10 carrying L9H had OR 0.36; standalone L9H had OR 0.45 per allele; combined with CFH variation, 74% of clinical outcomes were explained. Multiple subsequent meta-analyses confirmed the protection. A 2012 HuGE review and meta-analysis by Thakkinstian et al.⁵⁵ 2012 HuGE review and meta-analysis by Thakkinstian et al.
Pooled 19 studies, 2006–2011; rs4151667 A allele OR 0.54 (95% CI 0.45–0.64); absolute AMD risk reduction of 2–6% in Caucasians synthesised the population-level effect. A concurrent Sun et al. systematic review and meta-analysis⁶⁶ Sun et al. systematic review and meta-analysis
15 case-control studies; dominant model pooled OR 0.496 (95% CI 0.390–0.632, P<0.001) in Caucasians; protective effect weaker in Asians (AT/TT OR 0.68) corroborated the finding.

The protective effect is population-dependent: it is most consistently replicated in Europeans, where the A allele frequency is approximately 4–7%, while a negative case-control study in an Iranian cohort (n=407) found no significant association, likely reflecting differences in local LD patterns and haplotype backgrounds. The protective haplotype H10 (L9H + C2 E318D) contributes a 2–6% absolute risk reduction in Caucasian populations — modest in isolation, but large relative effects when AMD baseline risk is stratified by concomitant CFH risk genotype.

Functionally, the best evidence for the mechanism comes from the Heurich et al. 2011 PNAS complotype study⁷⁷ Heurich et al. 2011 PNAS complotype study
showed the full complement of common CFB, C3, and CFH polymorphisms can span a 6-fold range in hemolytic complement activity; the R32Q variant (in LD with the L9H haplotype background) reduces C3b binding affinity up to 4-fold, substantially lowering complement amplification.

Practical Actions

The protective A allele acts as a dampener on the alternative complement pathway. For heterozygous AT carriers, one copy reduces complement-driven drusen formation risk by approximately 40–50% per the population data. Homozygous AA carriers (rare, ~0.2% of Europeans) carry both copies of the protective allele and have the lowest complement-driven AMD risk from this locus.

While no supplement directly substitutes for this genetic protection, several complement pathway nutrients and lifestyle factors modulate AMD risk through overlapping pathways. The AREDS2 clinical trial formula (lutein/zeaxanthin + vitamin C + vitamin E + zinc/copper) is the only nutritional intervention with established AMD risk reduction in high-risk individuals, but its benefit is independent of CFB genotype. For AT and AA carriers, the primary actionable value lies in understanding their reduced genetic AMD risk — a meaningful counterweight to modifiable risk factors like smoking and UV exposure — while still maintaining standard AMD surveillance.

Interactions

rs4151667 is in near-complete LD with the C2 E318D variant (rs9332739), forming the H10 protective haplotype. Individuals carrying the rs4151667 A allele almost always also carry the rs9332739 C allele; the combined AMD protective effect is OR ~0.36 for the full H10 haplotype, stronger than either variant alone. The CFB R32Q variant (rs641153) provides AMD protection through a different mechanism (direct reduction in C3b binding affinity) on the independent H7 haplotype; carriers of both L9H and R32Q are exceptionally rare but would theoretically carry additive complement-dampening effects.

The L9H protective effect is most clinically relevant when assessed in the context of CFH Y402H (rs1061170) and ARMS2/HTRA1 variants — the dominant AMD risk loci. Carriers of the CFH 402H risk allele with CFB L9H protection represent a mixed-risk genetic profile where the classical-pathway (CFH) risk and alternative-pathway (CFB) protection partially offset each other. Formal risk score modelling incorporating CFH, ARMS2, and CFB variants explains the majority of AMD genetic risk in European populations.